Hydrogels have garnered significant attention for their versatile applications across various fields, including biomedical engineering. This review delves into the fundamentals of hydrogels, exploring their definition, properties, and classification. Hydrogels, as three-dimensional networks of crosslinked polymers, possess tunable properties such as biocompatibility, mechanical strength, and hydrophilicity, making them ideal for medical applications. Uniquely, this article offers original insights into the application of hydrogels specifically for corneal tissue engineering, bridging a gap in current research. The review further examines the anatomical and functional complexities of the cornea, highlighting the challenges associated with corneal pathologies and the current reliance on donor corneas for transplantation. Considering the global shortage of donor corneas, this review discusses the potential of hydrogel-based materials in corneal tissue engineering. Emphasis is placed on the synthesis processes, including physical and chemical crosslinking, and the integration of bioactive molecules. Stimuli-responsive hydrogels, which react to environmental triggers, are identified as promising tools for drug delivery and tissue repair. Additionally, clinical applications of hydrogels in corneal pathologies are explored, showcasing their efficacy in various trials. Finally, the review addresses the challenges of regulatory approval and the need for further research to fully realize the potential of hydrogels in corneal tissue engineering, offering a promising outlook for future developments in this field.

Background/Objectives: In recent years, the rapid advancements in artificial intelligence models, such as ChatGPT (version of 29 April 2024), have prompted interest from numerous domains of medicine, such as ophthalmology. As such, research is necessary to further assess its potential while simultaneously evaluating its shortcomings. Our study thus evaluates ChatGPT-4’s performance on the American Academy of Ophthalmology’s (AAO) Basic and Clinical Science Course (BCSC) Self-Assessment Program, focusing on its image recognition capabilities and its enhancement with domain-specific pretraining. Methods: The chatbot was tested on 1300 BCSC Self-Assessment Program questions, including text and image-based questions. Domain-specific pretraining was tested for performance improvements. The primary outcome was the model’s accuracy when presented with text and image-based multiple choice questions. Logistic regression and post hoc analyzes examined performance variations by question difficulty, image presence, and subspecialties. Results: The chatbot achieved an average accuracy of 78% compared with the average test-taker score of 74%. The repeatability kappa was 0.85 (95% CI: 0.82–0.87). Following domain-specific pretraining, the model’s overall accuracy increased to 85%. The accuracy of the model’s responses first depends on question difficulty (LR = 366), followed by image presence (LR = 108) and exam section (LR = 79). Conclusions: The chatbot appeared to be similar or superior to human trainee test takers in ophthalmology, even with image recognition questions. Domain-specific training appeared to have improved accuracy. While these results do not necessarily imply that the chatbot has the comprehensive skill level of a human ophthalmologist, the results suggest there may be educational value to these tools if additional investigations provide similar results.

In recent years, rapid advancements in glaucoma research have led to the development of more effective treatments of this chronic and irreversible condition. Of these, Kahook Blade Dual (KDB) goniotomy and second-generation trabecular micro-bypass stent (iStent) are two novel biomimetic procedures which have designs inspired by the eye’s natural drainage mechanisms. In this retrospective study, we evaluated the safety and effectiveness of both surgeries by including 176 eyes from 110 patients: 142 eyes in the iStent group and 34 in the KDB group. The primary outcomes of this study were the proportions of patients in each group attaining a 20% reduction in IOP and a post-operative IOP < 19 mmHg. At the last follow-up, a 20% reduction in IOP was achieved by 67% of iStent inject patients and 50% of KDB patients (p = 0.07). The iStent group also showed a higher proportion of patients reaching an IOP of less than 19 mmHg (81% vs. 71% in the KDB group, p = 0.13). The number of medications did not decrease in either group from pre-op to the last follow-up. The KDB group had more failures (29.4% vs. 4.2%) and a significantly higher adverse event rate than the iStent inject group (47.1% vs 12.0%).

Background/Objectives: Currently, treatments for age-related macular degeneration (AMD) consist of regular intravitreal injections that exert significant pressure on healthcare systems via their high labor costs and economic burden. To address this, our study’s goal is to propose new treatment protocols by comparing the efficacy of bimonthly fixed dosing aflibercept injections versus the treat-and-extend (T&E) approach for wet AMD. Secondary objectives included categorical best-corrected visual acuity (BCVA) changes, anatomical outcomes, treatment intervals, and adverse events. Methods: This study is a 1-year randomized, open-label, prospective trial that included 44 eyes from 44 patients, 32 in the T&E arm and 12 in the bimonthly arm. Treatment-naïve AMD patients with neovascularization were randomized to a bimonthly fixed dosing group or a T&E group after receiving 3 consecutive monthly aflibercept injections. Following the induction doses, retreatment intervals for patients in the T&E arm were adjusted based on a predetermined algorithm. Results: Over 12 months, mean BCVA improvements were 5.0 letters in the bimonthly group and 4.1 in the T&E group (p = 0.096 for non-inferiority test). On average, T&E patients received 9.6 injections compared to 7.7 for those in the fixed dosing group (p < 0.001). Anatomical outcomes were comparable in both treatment arms. Conclusions: In our trial, the T&E approach provided significant visual improvements, but did not meet the threshold for non-inferiority when compared to fixed bimonthly dosing. It was also unable to minimize treatment burden over the course of the first year of injections. Further research is required to optimize the T&E algorithm with aflibercept.